Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

The spindle assembly checkpoint is a therapeutic vulnerability of CDK4/6 inhibitor–resistant ER + breast cancer with mitotic aberrations
Isabel Soria‐Bretones, Kelsie L. Thu, Jennifer Silvester, et al.
Science Advances (2022) Vol. 8, Iss. 36
Open Access | Times Cited: 30

Showing 1-25 of 30 citing articles:

The CDK4/6 inhibitor revolution — a game-changing era for breast cancer treatment
Laura Morrison, Sibylle Loibl, Nicholas C. Turner
Nature Reviews Clinical Oncology (2023) Vol. 21, Iss. 2, pp. 89-105
Closed Access | Times Cited: 109
The two sides of chromosomal instability: drivers and brakes in cancer
Rendy Hosea, Sharon Hillary, S. Hassan R. Naqvi, et al.
Signal Transduction and Targeted Therapy (2024) Vol. 9, Iss. 1
Open Access | Times Cited: 43
PRMT5 is an actionable therapeutic target in CDK4/6 inhibitor-resistant ER+/RB-deficient breast cancer
Chang‐Ching Lin, Tsung-Cheng Chang, Yunguan Wang, et al.
Nature Communications (2024) Vol. 15, Iss. 1
Open Access | Times Cited: 16
Implantable, Biodegradable, and Wireless Triboelectric Devices for Cancer Therapy through Disrupting Microtubule and Actins Dynamics
Shuncheng Yao, Shaobo Wang, Minjia Zheng, et al.
Advanced Materials (2023) Vol. 35, Iss. 40
Closed Access | Times Cited: 30
Emerging systemic therapy options beyond CDK4/6 inhibitors for hormone receptor-positive HER2-negative advanced breast cancer
Jun Ma, Jack Junjie Chan, Ching Han Toh, et al.
npj Breast Cancer (2023) Vol. 9, Iss. 1
Open Access | Times Cited: 25
Seize the engine: Emerging cell cycle targets in breast cancer
Jesús Fuentes‐Antrás, Philippe L. Bédard, David W. Cescon
Clinical and Translational Medicine (2024) Vol. 14, Iss. 1
Open Access | Times Cited: 12
EGFR and HER2 hyper-activation mediates resistance to endocrine therapy and CDK4/6 inhibitors in ER+ breast cancer
Stefania Belli, Daniela Esposito, Claudia Maria Ascione, et al.
Cancer Letters (2024) Vol. 593, pp. 216968-216968
Open Access | Times Cited: 11
Perspectives and mechanisms for targeting mitotic catastrophe in cancer treatment
Zhaoshi Bai, Yiran Zhou, Yaling Peng, et al.
Biochimica et Biophysica Acta (BBA) - Reviews on Cancer (2023) Vol. 1878, Iss. 5, pp. 188965-188965
Closed Access | Times Cited: 19
Genome-guided discovery of cancer therapeutic targets
Prathyusha Konda, Simon Garinet, Eliezer M. Van Allen, et al.
Cell Reports (2023) Vol. 42, Iss. 8, pp. 112978-112978
Open Access | Times Cited: 14
CDK4/6 Inhibitor Resistance in ER+ Breast Cancer
Ilenia Migliaccio, Cristina Guarducci, Luca Malorni
Advances in experimental medicine and biology (2025), pp. 475-493
Closed Access
Targeting the mitotic kinase NEK2 enhances CDK4/6 inhibitor efficacy by potentiating genome instability
Jessica R. Bobbitt, Leslie Cuellar-Vite, Kristen L. Weber-Bonk, et al.
Journal of Biological Chemistry (2025), pp. 108196-108196
Open Access
Targeting TTK Inhibits Tumorigenesis of T‐Cell Lymphoma Through Dephosphorylating p38α and Activating AMPK/mTOR Pathway
Bingyu Liu, Tiange Lu, Mengfei Ding, et al.
Advanced Science (2025)
Open Access
JNK pathway suppression drives resistance to combination endocrine therapy and CDK4/6 inhibition in ER+ breast cancer
C. Elizabeth Caldon, Sarah Alexandrou, Christine Lee, et al.
Research Square (Research Square) (2025)
Open Access
Investigating Cisplatin Resistance in Squamous Cervical Cancer: Proteomic Insights into DNA Repair Pathways and Omics-Based Drug Repurposing
Amrita Mukherjee, S. Manna, Avinash Singh, et al.
Journal of Proteome Research (2025)
Closed Access
Significance of RB Loss in Unlocking Phenotypic Plasticity in Advanced Cancers
Varadha Balaji Venkadakrishnan, Yasutaka Yamada, Kenny Weng, et al.
Molecular Cancer Research (2023) Vol. 21, Iss. 6, pp. 497-510
Open Access | Times Cited: 10
Tumor suppressor heterozygosity and homologous recombination deficiency mediate resistance to front-line therapy in breast cancer
Anton Safonov, Antonio Marra, Chaitanya Bandlamudi, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2024)
Open Access | Times Cited: 3
Copy number alterations: a catastrophic orchestration of the breast cancer genome
Parastoo Shahrouzi, Farzaneh Forouz, Anthony Mathelier, et al.
Trends in Molecular Medicine (2024) Vol. 30, Iss. 8, pp. 750-764
Open Access | Times Cited: 3
Ionizable Drugs Enable Intracellular Delivery of Co‐Formulated siRNA
Kai V. Slaughter, Eric N. Donders, Michael S. Jones, et al.
Advanced Materials (2024) Vol. 36, Iss. 41
Open Access | Times Cited: 3
The Evolving Pathways of the Efficacy of and Resistance to CDK4/6 Inhibitors in Breast Cancer
Inês Gomes, Catarina Abreu, Luís Costa, et al.
Cancers (2023) Vol. 15, Iss. 19, pp. 4835-4835
Open Access | Times Cited: 8
Cyclin A/B RxL Macrocyclic Inhibitors to Treat Cancers with High E2F Activity
Shilpa Singh, Catherine E. Gleason, Min Fang, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2024)
Open Access | Times Cited: 2
Breaking through therapeutic barriers: Insights into CDK4/6 inhibition resistance in hormone receptor-positive metastatic breast Cancer
Yang Zheng, Zeyuan Zhang, Dan Li, et al.
Biochimica et Biophysica Acta (BBA) - Reviews on Cancer (2024) Vol. 1879, Iss. 5, pp. 189174-189174
Closed Access | Times Cited: 2
Exploring the Therapeutic Implications of Co-Targeting the EGFR and Spindle Assembly Checkpoint Pathways in Oral Cancer
Mafalda Calheiros-Lobo, João P. N. Silva, Bárbara Pinto, et al.
Pharmaceutics (2024) Vol. 16, Iss. 9, pp. 1196-1196
Open Access | Times Cited: 2
Acquired gene alterations in patients treated with ribociclib plus endocrine therapy or endocrine therapy alone using baseline and end-of-treatment circulating tumor DNA samples in the MONALEESA-2, -3, and -7 trials
Fabrice André, Nadia Solovieff, Fei Su, et al.
Annals of Oncology (2024)
Open Access | Times Cited: 2
Functional RNAi screening identifies G2/M and kinetochore components as modulators of TNFα/NF-κB pro-survival signaling in head and neck squamous cell carcinoma
Ethan L. Morgan, Anthony D. Saleh, Shaleeka Cornelius, et al.
Cancer Research Communications (2024) Vol. 4, Iss. 11, pp. 2903-2918
Open Access | Times Cited: 1
Acid‐Responsive Polymer Additives Increase RNA Transfection from Lipid Nanoparticles
Timothy H. Cheung, Alexander Fuchs, Molly S. Shoichet
Advanced Functional Materials (2024)
Open Access | Times Cited: 1
Page 1 - Next Page

Scroll to top